Višnja Tokić Pivac

Dr. Višnja Tokić Pivac

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2007 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
IBIngeborg Barisic
Ingeborg Barisic
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac
M:Maria :oane
Maria :oane
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi
ECEliza Calzolari
Eliza Calzolari
EGEUROCAT Working Group
EUROCAT Working Group

17 October 2006 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac
IBIngeborg Barisic
Ingeborg Barisic
NHNevenka Huzjak
Nevenka Huzjak
GPGiorgie Petkovic
Giorgie Petkovic
KFKsenija Fumic
Ksenija Fumic
EPEduard Paschke
Eduard Paschke

17 September 2019 in Pediatric Allergy, Immunology, and Pulmonology
Verified
Journal Article
Closed access
NSNusa Matijasic Stjepovic
Nusa Matijasic Stjepovic
ABAleksandra Bonevski
Aleksandra Bonevski
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac
IPIvan Pavic
Ivan Pavic
Background: Impaired lung function has been detected in up to 65% of all childhood cancer survivors. It is often caused by exposure to radiation therapy and various chemotherapeutics. The first cytotoxic drug ever identified as a causative agent of lung injury was busulfan, reported in the early 1960s. Signs and symptoms of busulfan lung are nonspecific and it is therefore difficult to differentiate the condition from pulmonary impairment caused by other pulmotoxic agents, infections, pulmonary metastases, graft-versus-host disease, or other noninfectious post-transplant complications involving the lungs. Methods: A case example is provided to illustrate the difficulties in management of busulfan-induced lung injury in children. A retrospective review of cases of busulfan-induced lung injury indexed in PubMed until March 2019 was performed. Inclusion criteria for articles was available in full text in English. Results: Impaired lung function caused by busulfan may become an increasing problem for young survivors. Conclusion: Newly developed dyspnea or subclinical damage detected on pulmonary function tests, indicating primarily restrictive disease, should always arouse suspicion of busulfan-induced lung injury in a child conditioned with busulfan, especially after excluding other leading culprits of pulmonary damage affecting oncology patients.

1 February 2013 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
ZPZ. Pleša Premilovac
Z. Pleša Premilovac
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac

10 February 2023 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac
VHVesna Herceg-Čavrak
Vesna Herceg-Čavrak
IHIva Hojsak
Iva Hojsak
ZMZrinjka Mišak
Zrinjka Mišak
OJOleg Jadresin
Oleg Jadresin
SKSanja Kolacek
Sanja Kolacek

21 May 2026 in Children
Verified
Journal Article
Open access
PDF file
Višnja Tokić PivacVišnja Tokić Pivac
Višnja Tokić Pivac
SKSanja Kolacek
Sanja Kolacek
IHIva Hojsak
Iva Hojsak
ZMZrinjka Mišak
Zrinjka Mišak
OJOleg Jadresin
Oleg Jadresin
Ivan PavićIvan Pavić
Ivan Pavić
Objectives: We aimed to assess fractional exhaled nitric oxide (FeNO) and spirometry in pediatric patients with inflammatory bowel disease (IBD) and relate these parameters to disease activity, duration, and current treatment. Methods: This prospective case–control study included 161 subjects: children with newly diagnosed, active IBD (N = 55), children in clinical remission (N = 53), and healthy controls (N = 53). FeNO was measured using a chemiluminescent analyzer, and pulmonary function was assessed by spirometry. Results: FeNO was higher in patients with IBD than in controls (p = 0.025) and positively correlated with CRP (ρ = 0.22; p = 0.027). Respiratory function measured by spirometry in children with IBD was preserved. No association was found between respiratory parameters, disease activity, and duration. The correlation between FeNO and aminosalicylate treatment was of borderline significance (ρ = 0.28; p = 0.052). Conclusions: Children with IBD, although having normal pulmonary function measured by spirometry, do have increased FeNO, which is positively correlated with CRP. FeNO reflects systemic inflammation, but its role as a clinical marker of disease activity or relapse remains uncertain.